[Skip to Content]
[Skip to Content Landing]
Views 1,156
Citations 0
Editorial
November 28, 2017

The Public Health Consequences of Performance-Enhancing SubstancesWho Bears Responsibility?

Author Affiliations
  • 1Division of Metabolism, Diabetes, and Endocrinology, Department of Internal Medicine, University of Michigan, Ann Arbor
  • 2Department of Pharmacology, University of Michigan, Ann Arbor
  • 3Department of Psychiatry and Addiction Research Center, University of Michigan, Ann Arbor
JAMA. 2017;318(20):1983-1984. doi:10.1001/jama.2017.17111

The nonmedical use of performance-enhancing substances, particularly androgens and related drugs, has been a global public health problem for several decades.1,2 A meta-analysis of 271 studies published between 1970 and 2013 estimated lifetime prevalence rates of 6.4% among males and 1.6% among females.1 The use of banned performance-enhancing drugs in elite sports has received much attention but is merely the tip of the iceberg.

First Page Preview View Large
First page PDF preview
First page PDF preview
×